SV2002000343A - Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb - Google Patents

Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb

Info

Publication number
SV2002000343A
SV2002000343A SV2001000343A SV2001000343A SV2002000343A SV 2002000343 A SV2002000343 A SV 2002000343A SV 2001000343 A SV2001000343 A SV 2001000343A SV 2001000343 A SV2001000343 A SV 2001000343A SV 2002000343 A SV2002000343 A SV 2002000343A
Authority
SV
El Salvador
Prior art keywords
glucogeno
pharmaceutical
fosforilasa
composisions
ref
Prior art date
Application number
SV2001000343A
Other languages
English (en)
Inventor
Dennis Jay Hoover
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2002000343A publication Critical patent/SV2002000343A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UN INHIBIDOR DE LA GLUCOGENO-FOSFORILASA Y COMO MINIMO UN POLIMERO QUE AUMENTA LA CONCENTRACION. LA COMPOSICION PUEDE SER UNA MEZCLA FISICA SIMPLE DE UN INHIBIDOR DE LA GLUCOGENO-FOSFORILASA Y UN POLIMERO QUE AUMENTA LA CONCENTRACION, O UNA DISPERSION DE UN INHIBIDOR DE LA GLUCOGENO-FOSFORILASA Y UN POLIMERO.
SV2001000343A 2000-03-16 2001-03-15 Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb SV2002000343A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
SV2002000343A true SV2002000343A (es) 2002-07-03

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000343A SV2002000343A (es) 2000-03-16 2001-03-15 Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb

Country Status (32)

Country Link
US (1) US20010053778A1 (es)
EP (1) EP1263414A1 (es)
JP (1) JP2003526654A (es)
KR (1) KR20020081445A (es)
CN (1) CN1418089A (es)
AP (1) AP2002002621A0 (es)
AR (1) AR027656A1 (es)
AU (1) AU2001242669A1 (es)
BG (1) BG107037A (es)
BR (1) BR0109189A (es)
CA (1) CA2403241A1 (es)
CO (1) CO5280087A1 (es)
CZ (1) CZ20022955A3 (es)
EA (1) EA200200858A1 (es)
EE (1) EE200200530A (es)
HU (1) HUP0204583A2 (es)
IL (1) IL151320A0 (es)
IS (1) IS6508A (es)
MA (1) MA26882A1 (es)
MX (1) MXPA02009097A (es)
NO (1) NO20024386L (es)
OA (1) OA12232A (es)
PA (1) PA8513601A1 (es)
PE (1) PE20011184A1 (es)
PL (1) PL360780A1 (es)
SK (1) SK12622002A3 (es)
SV (1) SV2002000343A (es)
TN (1) TNSN01040A1 (es)
TR (1) TR200202184T2 (es)
WO (1) WO2001068055A1 (es)
YU (1) YU67202A (es)
ZA (1) ZA200207290B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43702A (sh) * 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
MXPA03011784A (es) * 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN107602710A (zh) 2012-08-24 2018-01-19 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
CN105307636A (zh) * 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations
US20250241586A1 (en) * 2024-01-04 2025-07-31 Debasish Banerjee Bioavailability and bioequivalence through intrinsic activity and KD measurements, in vivo, in humans

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9709875A (es) * 1995-06-06 1998-03-31 Pfizer N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
AP2002002621A0 (en) 2002-09-30
WO2001068055A1 (en) 2001-09-20
IL151320A0 (en) 2003-04-10
NO20024386L (no) 2002-11-13
TNSN01040A1 (fr) 2005-11-10
CN1418089A (zh) 2003-05-14
PE20011184A1 (es) 2001-11-15
EA200200858A1 (ru) 2003-02-27
ZA200207290B (en) 2003-09-11
MXPA02009097A (es) 2003-03-12
EP1263414A1 (en) 2002-12-11
CZ20022955A3 (cs) 2003-09-17
BR0109189A (pt) 2003-05-27
YU67202A (sh) 2006-01-16
BG107037A (bg) 2003-04-30
IS6508A (is) 2002-08-16
NO20024386D0 (no) 2002-09-13
PL360780A1 (en) 2004-09-20
KR20020081445A (ko) 2002-10-26
US20010053778A1 (en) 2001-12-20
AR027656A1 (es) 2003-04-09
PA8513601A1 (es) 2004-08-31
TR200202184T2 (tr) 2003-01-21
JP2003526654A (ja) 2003-09-09
OA12232A (en) 2006-05-10
HUP0204583A2 (hu) 2003-04-28
SK12622002A3 (sk) 2004-02-03
EE200200530A (et) 2004-04-15
CA2403241A1 (en) 2001-09-20
AU2001242669A1 (en) 2001-09-24
CO5280087A1 (es) 2003-05-30
MA26882A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
PA8513601A1 (es) Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa
SV2004001473A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo ref.pc 23132
PA8523901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester
BR0207296B1 (pt) composiÇço para revestimento.
BR0006005A (pt) Composição estável de óleo em glicerinatopicamente aplicável
DE69928938D1 (de) Neues cyclosporin mit verbesserter wirkung
BR0101304B1 (pt) "composição de poliolefina que compreende uma mistura de absorvedores de uv e uso de uma mistura de absorvedores de uv".
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
BR0215405A (pt) Composições e processos de uso de collajolie
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
DE69905170T2 (de) Thiazolopyrimidinderivate
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
BG104916A (en) Calcilytic compounds
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
AU2001275346A1 (en) Compositions, kits, and methods for identification and modulation of type i diabetes
NO20011017L (no) Polymeriserings-inhibitering av styren-monomerer
NO20031860L (no) Kahalalid F
BR0000544A (pt) Poliolefinas de metaloceno estabilizadas
BR0210096A (pt) Composição farmacêutica contendo emoliente de fezes tal como poloxâmero e partìculas entéricas revestidas de bissacodil
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
DE50107490D1 (de) Stoffgemisch enthaltend bisphenol a
AR031404A1 (es) Una composicion y metodo de aplicacion

Legal Events

Date Code Title Description
FD Lapse